Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Research trends in endocrinology, diabetes and metabolism

Research trends in endocrinology, diabetes and metabolism

Automated glucose management, incretin pharmacology, and a metabolic liver disease that changed its name to change its diagnosis.

Endocrinology, diabetes and metabolism

Technology in type 1 diabetes

Continuous glucose monitoring is standard of care in much of the world, and automated insulin delivery — pump and sensor coupled by a control algorithm — is established therapy rather than a research prospect.

The outcome measures changed with the technology. Time in range, time below range and glycaemic variability derived from CGM now supplement HbA1c, which averages over months and conceals hypoglycaemia. International consensus targets for these exist and should be used rather than invented per study.

Immunotherapy to delay progression in people at high risk of type 1 diabetes has moved from concept to established approach, shifting attention toward screening to identify those at risk.

Incretin pharmacology

GLP-1 receptor agonists and dual GLP-1/GIP agonists have effects extending beyond glycaemia to weight, cardiovascular and renal outcomes, which has blurred the boundary between diabetes, obesity and cardiorenal medicine. Treatment choice in type 2 diabetes is increasingly driven by comorbidity rather than by glucose lowering alone.

Metabolic liver disease

Nomenclature changed: non-alcoholic fatty liver disease was reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), with positive metabolic criteria rather than exclusion of alcohol. This is not cosmetic — it changes who is diagnosed, so prevalence figures and cohorts across the nomenclature change are not directly comparable.

Reporting

State which diagnostic criteria and nomenclature were used and when the cohort was assembled. Report CGM metrics against consensus definitions. For cardiorenal outcomes, report absolute as well as relative effects.

In short

What to take from this.

  • State the nomenclature: MASLD and NAFLD cohorts are not interchangeable.
  • Use consensus CGM metric definitions rather than study-specific ones.
  • HbA1c conceals hypoglycaemia; report time below range.

Sources

  • International consensus on continuous glucose monitoring metrics
  • MASLD nomenclature consensus statements

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.